Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

Abstract : AbstractBackgroundCOU-AA-301 trial has proved that abiraterone acetate (AA), a selective inhibitor of androgen biosynthesis, improved overall survival (OS) of patients with metastatic castration resistant prostate cancer (mCRPC) after a first line of docetaxel. Based on this result, a Temporary Authorization for Use (TAU) was performed between December 2010 and July 2011 to provide patients with mCRPC the opportunity to receive AA before its commercialization. The aim of this study was to evaluate safety and efficacy of AA treatment in this TAU.MethodsBetween December 2010 and July 2011, we conducted an ambispective, multicentric cohort study and investigated data from 20 centres participating to the AA TAU for patients presenting mCRPC and already treated by a first line of chemotherapy (CT). Statistical analyses of the data were performed using the Stata software v13 to identify predictive and prognostic factors.ResultsAmong the 408 patients, 306 were eligible with a follow-up at 3 years. Median OS was 37.1 months from beginning of CT and 14.6 months from AA introduction. 211 patients (69%) received ≥ 3 months of AA and 95 patients (31%) were treated less than 3 months. In the multivariate analyses, duration of AA was significantly correlated with PSA decrease at 3 months. Additionally, shorter time under AA treatment, presence of multiple sites of metastasis and previous hormonal treatment duration were three independent factors associated with poorer OS. At the time of analysis ten patients were still under treatment for more than 3 years.ConclusionsBiochemical response monitored by PSA changes at 3 months is a strong predictive factor for AA treatment duration. Some high responders’ patients could beneficiate from AA for more than 3 years.
Type de document :
Article dans une revue
BMC Cancer, BioMed Central, 2015, 15 (1), pp.222. 〈10.1186/s12885-015-1257-2〉
Liste complète des métadonnées

Littérature citée [22 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01264474
Contributeur : Bmc Bmc <>
Soumis le : vendredi 29 janvier 2016 - 12:42:22
Dernière modification le : vendredi 9 février 2018 - 01:07:07
Document(s) archivé(s) le : vendredi 11 novembre 2016 - 20:09:48

Fichier

12885_2015_Article_1257.pdf
Publication financée par une institution

Identifiants

Citation

Nadine Houédé, Philippe Beuzeboc, Sophie Gourgou, Diego Tosi, Laura Moise, et al.. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. BMC Cancer, BioMed Central, 2015, 15 (1), pp.222. 〈10.1186/s12885-015-1257-2〉. 〈inserm-01264474〉

Partager

Métriques

Consultations de la notice

134

Téléchargements de fichiers

52